%20(2).png){kind=logo}
AI stocks fell on investor concerns, but experts see the drop as a needed correction that will separate hype from real value while supporting long-term growth.
Trump is pushing drugmakers to expand direct-to-consumer sales with MFN pricing, but industry leaders resist steep cuts and experts warn of risks to patient care.
A California jury found that Meta was “eavesdropping” in women’s health data. This decision has implications on the future of health privacy.
Fierce Pharma features Ostro’s analysis on why 65% of HCP digital interactions lead nowhere—and how AI-powered journey orchestration can change that.
Digital health leaders welcomed Trump’s AI Action Plan for promoting innovation through deregulation and data standards but flagged gaps in AI safety, patient consent, and regulatory oversight.
Industry leaders are bracing for Trump’s new reciprocal tariffs and the threat of steep biopharma duties that could disrupt global drug trade despite WTO rules.
Ostro is a 2025 Fierce Pharma Marketing Awards finalist in the "New Brand Launch" category for its work on the Ostro x BridgeBio Attruby launch.
.svg)